How to Use AI in Drug Development Without Creating Compliance Risk
- 0:00 Why This Matters Now
- 3:00 Where AI Fits Safely
- 11:00 Risk Map For Regulated Use
Practical shifts you can apply this week
-
Identify Lower-Exposure AI Uses
Spot workflow candidates where AI helps with drafting, search, and checks without driving regulated decisions.
-
Evaluate Tasks With Risk Lens
Assess GxP impact, data sensitivity, and review needs before a pilot turns into a finding.
-
Compare Acceptable Tool Uses
See where public and enterprise tools fit, and where they create privacy, IP, or documentation trouble.
-
Design Minimum Guardrails
Set simple controls for prompts, outputs, review, and records so teams can move with less guesswork.
-
Draft A Pilot Plan
Leave with a one-page approach that can stand up to questions from QA, Legal, and IT.
What we'll cover
-
0:00
Why This Matters Now
A practical frame for using AI in drug development without creating avoidable compliance risk.
-
3:00
Where AI Fits Safely
Bounded tasks like drafting, summarizing, searching, and quality checks versus autonomous decisions.
-
11:00
Risk Map For Regulated Use
How GxP impact, sensitive data, vendor dependence, and weak review raise risk in predictable ways.
-
21:00
Use Cases Worth Piloting
Medical writing, TMF support, safety triage, and regulatory intelligence where humans stay accountable.
-
30:00
Red Flags And Failures
Hallucinations, prompt leakage, automation bias, and missing audit trails. Fluent text is not evidence.
-
35:00
Guardrails Before Go-Live
Approved tools, data rules, review checklists, and documentation that reduce risk without freezing progress.
-
40:00
Validation, Vendors, Pilot Plan
Match evidence to intended use, ask better vendor questions, and sketch a 30-day pilot brief.
-
44:00
Recap And Live Q&A
Bring one real workflow and pressure-test it with the session's risk screen and guardrails.
Questions people ask before registering
-
It is built for working professionals in drug development, clinical, regulatory, quality, safety, medical writing, and R&D operations. If AI keeps landing on your desk with a side of compliance anxiety, you are in the right room.
-
No. The session is designed for operational and functional teams, not data scientists. We focus on practical decisions, common workflows, and the controls that matter in regulated settings.
-
Yes. A core section compares acceptable and unacceptable uses of public and enterprise tools, with examples involving patient data, confidential content, and approved internal sources.
-
If a replay is being offered by the host, registered attendees typically receive access after the session. Check the registration details or confirmation email for the final policy.
-
Yes. You will leave with a simple risk screen and a one-page pilot brief structure you can review with QA, Legal, and IT next week.
-
Certificates or CE credit depend on the event host's policy. If they are available, the registration page or follow-up email will include the details.